Related Experiment Video
Updated: Oct 28, 2025

04:04
Asthma Detection Research Based on Voice Signal Processing and Machine Learning
Published on: July 22, 2025
572
Dementia risks identified by vocal features via telephone conversations: A novel machine learning prediction model
Akihiro Shimoda1, Yue Li1, Hana Hayashi1,2,3
1Department of Public Health, McCann Healthcare Worldwide Japan Inc., Tokyo, Japan.
Plos One
|July 14, 2021
Summary
Early Alzheimer's disease (AD) detection can be improved using vocal features from daily conversations. Machine learning models analyzing speech show promise for accessible AD risk assessment, outperforming traditional cognitive tests.
Area of Science:
- Neurology and Artificial Intelligence
- Biomedical Engineering
- Gerontology
Background:
- Current Alzheimer's disease (AD) diagnosis methods are costly and lack accessibility for early detection.
- Preclinical AD risk identification requires low-cost, reliable tools.
- Cognitive decline in AD may manifest in vocal characteristics during everyday speech.
Purpose of the Study:
- To develop and evaluate a novel machine learning (ML) model for identifying preclinical Alzheimer's disease (AD) risk using vocal features from daily conversations.
- To compare the predictive performance of the ML vocal analysis model against the Japanese version of the Telephone Interview for Cognitive Status (TICS-J).
Main Methods:
- Collected 1,616 audio recordings from 99 healthy controls (HC) and 24 AD patients.
- Extracted vocal features and developed ML models (XGBoost, Random Forest, Logistic Regression) for AD risk prediction.
- Evaluated model performance using ROC curves, AUCs, sensitivity, and specificity, comparing audio-based and participant-based predictions with TICS-J.
Main Results:
- Participant-based prediction models achieved high Area Under the Curve (AUC) values: XGBoost (1.000), Random Forest (1.000), and Logistic Regression (0.972).
- The ML models showed comparable or superior predictive performance to the TICS-J (AUC: 0.917).
- The novel vocal feature analysis demonstrated significant potential for AD risk assessment.
Conclusions:
- Vocal features extracted from daily conversations can be effectively utilized by machine learning models for Alzheimer's disease (AD) risk assessment.
- This approach offers a potentially low-cost, accessible, and reliable tool for preclinical AD detection.
- Further validation is warranted to integrate this technology into clinical practice for early AD risk stratification.
More Related Videos
Related Concept Videos
Dementia
256
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
256
Alzheimer's Disease: Overview
887
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
887
Alzheimer's Disease: Treatment
423
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
423

